Ascidian Therapeutics

About:

Ascidian Therapeutics is a biotechnology company that focuses on medical and clinical gene therapy.

Website: https://www.ascidian-tx.com/

Top Investors: Apple Tree Partners

Description:

Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs.

Total Funding Amount:

$90M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Boston, Massachusetts, United States

Founded Date:

2020-01-01

Contact Email:

info(AT)ascidian-tx.com

Founders:

Michael Ehlers

Number of Employees:

11-50

Last Funding Date:

2023-11-08

IPO Status:

Private

Industries:

© 2025 bioDAO.ai